Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-19 Earnings release - Q2 2026

More about the company

Market Cap	98.98M 10.43M 9.07M 8.44M 7.75M 14.63M 996M 14.86M 99.49M 39.05M 496M 39.18M 38.32M 1.66B	P/E 2026 *	-0.87x	P/E 2027 *	-1.19x
Enterprise Value	135M 14.23M 12.37M 11.51M 10.57M 19.96M 1.36B 20.27M 136M 53.25M 676M 53.43M 52.25M 2.27B	EV / Sales 2026 *	-	EV / Sales 2027 *	27.4x
Free-Float	89.66%	Yield 2026 *	-	Yield 2027 *	-

07-02	Lifecare Completes Production Transfer and Provides Update on Longevity Programme	CI
06-29	Lifecare Transfers Operations from Germany to Norway, UK	MT
06-26	Lifecare ASA Discontinues Operations of Lifecare Germany GmbH	CI
06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
05-15	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Lifecare Q1 operating loss NOK 31.5 mln	RE
04-23	Lifecare ASA Approves Board Appointments	CI
03-26	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
03-26	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
03-26	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
03-16	Lifecare Chief Scientific Officer to Step Down	MT
03-13	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI

07-02	LIFE: Update on production transfer and longevity programme	AQ
06-26	LIFE: Operational update regarding Lifecare Germany GmbH (i.L)	PU
06-22	LIFE: Independent tissue analysis confirms no adverse tissue response after six months of implantation	AQ
06-12	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
06-10	Lifecare ASA: Mandatory notification of trade	PU

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	06/09/2020
Petter Nielsen DFI	Director of Finance/CFO	-	31/03/2026
Torsten Ernst PRN	Corporate Officer/Principal	-	29/02/2024

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	25/06/2020
Morten Foros Krohnstad CHM	Chairman	-	07/05/2021
Lutz Heinemann BRD	Director/Board Member	-	19/11/2020

Lifecare AS Share Price Oslo Bors

Stocks

NO0010591191

Biotechnology & Medical Research

Valuation: Lifecare AS

Latest news : Lifecare AS

Last Transcript: Lifecare AS

Analysts' recommendations: Lifecare AS

Press Releases: Lifecare AS

News in other languages: Lifecare AS

Managers and Directors: Lifecare AS

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE AS	-.--%	-4.31%	-	-	10.91M
LONZA GROUP AG	-1.40%	+3.69%	-2.09%	+11.41%	49.37B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+26.45%	+5.03%	39.14B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+403.17%	+614.40%	40.85B
BEONE MEDICINES AG	-1.88%	-3.03%	+4.94%	+47.52%	35.81B
CELLTRION, INC.	-1.74%	+8.42%	+8.85%	+48.87%	30.5B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.55B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+35.09%	+127.95%	16.14B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-3.32%	-34.94%	12.77B
EUROFINS SCIENTIFIC SE	-0.64%	+3.09%	+3.15%	+9.37%	13.71B
Average	-1.32%	+5.78%	+59.53%	+103.70%	28.32B
Weighted average by Cap.	-1.42%	+6.72%	+77.29%	+129.25%

	2026 *	2027 *
Net sales	-	5M 527K 458K 426K 391K 739K 50.31M 751K 5.03M 1.97M 25.04M 1.98M 1.94M 83.98M
Net income	-86M -9.06M -7.88M -7.33M -6.73M -12.72M -865M -12.91M -86.45M -33.93M -431M -34.04M -33.29M -1.44B	-82M -8.64M -7.51M -6.99M -6.42M -12.12M -825M -12.31M -82.43M -32.35M -411M -32.46M -31.75M -1.38B
Net Debt	36M 3.79M 3.3M 3.07M 2.82M 5.32M 362M 5.41M 36.19M 14.2M 180M 14.25M 13.94M 605M	38M 4.01M 3.48M 3.24M 2.98M 5.62M 382M 5.71M 38.2M 14.99M 190M 15.04M 14.71M 638M